secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001606498-23-000067
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos clarifies Q2 2023 results beat consensus after third-party error
-----------------------------------------------------------------------

- Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.
- Adjusted diluted EPS including discontinued ops was $0.37, ahead of consensus.
- Continuing operations: net sales $169.4M, diluted loss per share $0.09, adjusted EPS $0.24.
- RH business operating results reported as discontinued operations due to planned divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/0001606498-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/avns-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001606498-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer